Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July

Executive Summary

Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year

You may also be interested in...



Biovail Cardizem XL “approvable”

Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...

Biovail Cardizem XL “approvable”

Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...

Biovail Cardizem XL NDA Highlights Nighttime Dose For Cardiac AE Prevention

Biovail's NDA for hypertension agent Cardizem XL (diltiazem) highlights nighttime dosing aimed at achieving maximum drug levels between 6 a.m. and noon, when the majority of adverse cardiac events take place.

UsernamePublicRestriction

Register

PS039848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel